• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avista Public Acquisition Corp. II - Class A Ordinary Shares (NQ:AHPA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Nov 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 5.200 (10)
Ask (Size) 6.280 (1)
Prev. Close 6.125
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday ↗
October 31, 2022
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. 
Via Benzinga
News headline image
OmniAb Business Combination Approved by APAC Shareholders
October 24, 2022
From Ligand Pharmaceuticals Incorporated
Via Business Wire

Performance

More News

Read More
News headline image
Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗
October 28, 2022
Via Benzinga
News headline image
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients ↗
August 25, 2022
Via Benzinga
News headline image
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
August 24, 2022
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Second Quarter 2022 Financial Results
August 08, 2022
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports First Quarter 2022 Financial Results
May 04, 2022
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗
March 24, 2022
Via Benzinga
News headline image
Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger ↗
March 24, 2022
Via Benzinga
News headline image
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
March 23, 2022
From Ligand Pharmaceuticals Incorporated
Via Business Wire

Frequently Asked Questions

Is Avista Public Acquisition Corp. II - Class A Ordinary Shares publicly traded?
Yes, Avista Public Acquisition Corp. II - Class A Ordinary Shares is publicly traded.
What exchange does Avista Public Acquisition Corp. II - Class A Ordinary Shares trade on?
Avista Public Acquisition Corp. II - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Avista Public Acquisition Corp. II - Class A Ordinary Shares?
The ticker symbol for Avista Public Acquisition Corp. II - Class A Ordinary Shares is AHPA on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap